Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Newly identified genes may help predict outcome in childhood leukemia

08.12.2003


The measurement of new genes at diagnosis in children with acute lymphoblastic leukemia (ALL), discovered through new technologies from the human genome project, may be highly predictive of therapeutic outcomes, according to a study presented today during the 45th Annual Meeting of the American Society of Hematology (ASH). OPAL 1 (Outcome Predictor in Acute Leukemia 1), a novel, fully cloned human gene, and additional newly identified genes, have a strong predictive power to identify patients who may achieve remission or fail current therapeutic regimens for pediatric ALL, allowing physicians to tailor therapies more effectively to individual children with leukemia.



Study results showed that 87 percent of the patients with ALL and high OPAL 1 achieved long-term remission, compared to an overall outcome of 32 percent of all patients studied. OPAL1 was also highly predictive of a favorable outcome in T-cell ALL, and a similar trend was observed in infant ALL. Low OPAL1 was associated with induction failure, while high OPAL1 was associated with long-term event free survival, particularly in males. Eighty-six percent of ALL cases with t(12;21), which has prognostic value in ALL, and high OPAL1 achieved long term remission compared to only 35 percent of t(12;21) cases with low OPAL1, suggesting that OPAL1 may be useful in prospectively identifying children who may benefit from further intensification.

"Our study confirms that gene expression profiling can yield novel genes that may be used to improve risk classification and outcome prediction in acute leukemia in children," said Cheryl L. Willman, M.D., of the University of New Mexico Health Sciences Center, Albuquerque, N.M., senior author of the study. "Improving risk classification schemes in order to precisely tailor treatment regimens to individual patients has long been a major challenge for pediatric ALL, and is a goal of the National Children’s Oncology Group and the National Cancer Institute, which have supported our work. We believe that our research brings us closer to achieving this goal."


Current treatments, usually combination chemotherapy and post-induction therapeutic intensification (increasingly stronger treatment administered after initial therapy), currently help 75 percent of children with ALL achieve long-term remission. Yet, 25 percent of patients relapse with resistant disease. Additionally, 25 percent of patients who receive dose intensification treatment are often over-treated and may be cured using less intensive regimens with fewer acute and long-term side effects.

To identify strongly predictive genes, researchers performed gene expression profiling in two large, statistically designed, retrospective groups of pediatric ALL patients registered to trials previously conducted by the Pediatric Oncology Group (now merged with other national groups into the Children’s Oncology Group) – a group of 127 infant leukemia patients and a case control study of 254 children with B-precursor and T-cell ALL. Researchers used unsupervised learning tools and supervised machine learning algorithms to identify novel genes that were predictive of outcomes. Three strong genes were identified with both testing methods – G0, an expressed sequence tag of previously unknown function; G1:GNB2L1, a G-protein (a second messenger receptor of intracellular response) and activator of protein kinase C, which plays a pivotal role in cell signaling systems; and G2, an interleukin (IL)-10 receptor alpha, which regulates immune and inflammatory response. ALL cases expressing higher levels of these genes were associated with better outcomes. As the group fully cloned and characterized the G0 expressed sequence tag, it was given the new name of OPAL1.

"Studies to profile gene expressions in cancers like leukemia are very timely because physicians still need to better predict therapeutic responses," said Ronald Hoffman, M.D., President of the American Society of Hematology. "While we can already use a combination of chemotherapy and post-therapeutic treatments to help most children with ALL achieve remission, it is still difficult to know which patients will experience a relapse in the disease when they become resistant to the therapy. Hopefully the identification of new genes will help hematologists more accurately treat patients."

Leukemia is a cancer of the white blood cells that starts in the bone marrow and spreads to the blood, lymph nodes, and other organs. Both children and adults can develop leukemia, which is a complex disease with many different types and sub-types. The kind of treatment given and the outlook for childhood leukemia vary greatly according to the exact type and other individual factors. In acute leukemia the cells grow rapidly and are not able to mature properly. According to the National Cancer Institute, the vast majority of children diagnosed with leukemia have an acute form of the disease. Leukemias account for more than 30 percent of childhood cancers in children younger than 15 years old; three-fourths of those cases are ALL. The disease is not known as an inherited type, but there is evidence that it tends to cluster in families with high incidences of cancer.


###
The American Society of Hematology is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Aimee Frank | EurekAlert!
Further information:
http://www.hematology.org/

More articles from Life Sciences:

nachricht Scientists uncover the role of a protein in production & survival of myelin-forming cells
19.07.2018 | Advanced Science Research Center, GC/CUNY

nachricht NYSCF researchers develop novel bioengineering technique for personalized bone grafts
18.07.2018 | New York Stem Cell Foundation

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>